New Pill Shows Promise in Slowing Early Alzheimer's Progression
A Phase 3 trial of the investigational drug valiltramiprosate shows promise in slowing neurodegeneration in genetically high-risk Alzheimer's patients with APOE4/4, especially when administered early at the MCI stage, though it did not meet its primary clinical endpoint overall.